Enzyme News and Research

RSS

Trop-2 new target for anti-tumour therapy in cancer

Italian scientists announced (Monday September 24) that they have found a new and promising target for anti-tumour therapy in cancer.

25 Sep 2007

Social cheating in bacterial communication

Baseball had its steroids and Black Sox. Politics lived through Watergate. Wall Street has been riddled with insider trading scandals. And before we cast the first stone, who among us has never tried to get through an intersection on a yellow light?

25 Sep 2007

Infections caused by ESBL-producing E. coli

In light of increased media and public interest in ESBL-producing E. coli, the UK's Health Protection Agency felt it would be helpful to provide some background about these infections and the work that is being carried out in this area.

24 Sep 2007

Scientists say fewer calories equals longer life

Even though scientists already knew at least as far as animals are concerned, that reducing the calorie intake was linked to longevity, they never really knew why.

24 Sep 2007

MIT model could improve some drugs' effectiveness

MIT researchers have developed a computer modeling approach that could improve a class of drugs based on antibodies, molecules key to the immune system.

24 Sep 2007

Why some people find it so difficult to stop smoking

Mark Twain boasted that it was easy to quit smoking because he did it every day.

24 Sep 2007

Study reveals the regulatory mechanism of protein kinase A

Research conducted at the University of California, San Diego (UCSD) School of Medicine has shed new light on the structure and function of one of the key proteins in all mammalian cells, protein kinase A (PKA), an enzyme which plays an essential role in memory formation, communication between nerve cells, and cardiac function.

21 Sep 2007

Two genes in mammalian cells act as gatekeepers for cellular longevity

In everything from yeast to primates, a significant decrease in calories can extend lifespan by as much as one-third. But getting under the hood of the molecular machinery that drives this longevity has remained elusive.

21 Sep 2007

Process of necrosis redefined in landmark study

A new study led by investigators from the University of Pittsburgh School of Medicine demonstrates that the process of necrosis, long thought to be a chaotic, irreversible pathway to cell death, may actually be triggered as part of a regulated response to stress by a powerful protein, SRP-6, that can potentially halt necrosis in its path.

21 Sep 2007

Genetic variation affects smoking cessation treatment

Mark Twain boasted that it was easy to quit smoking because he did it every day.

21 Sep 2007

Researchers question genetic screening programs

The study by a team at Shaare Zedek Medical Centre in Jerusalem, is the first to examine what couples actually did when they learned their unborn child had a condition called Gaucher disease, an inherited condition which can be effectively treated.

20 Sep 2007

Study examines implications of genetic screening for disease that can be less serious, treatable

Some couples in Israel whose fetus screened positive for Gaucher disease, which can range from being mild and treatable to being a severe disease, decided to have the pregnancy terminated, raising questions concerning the appropriateness of certain types of genetic screenings, according to a study in the September 19 issue of JAMA.

18 Sep 2007

Researchers genetically engineering microorganisms, such as E. coli, into tiny, cellular factories

Microorganisms may soon be efficiently and inexpensively producing novel pharmaceutical compounds, such as flavonoids, that fight aging, cancer or obesity, as well as high-value chemicals, as the result of research being conducted by University at Buffalo researchers.

18 Sep 2007

Liver cancer marker could yield blood test for early detection

In the face of an emerging liver cancer crisis in Asia, researchers at the Chinese University of Hong Kong have developed a test that could help millions.

18 Sep 2007

Helix BioPharma awarded U.S. patent for adjunct chemotherapy applications

Helix BioPharma Corp. has announced the issuance of its second DOS47 patent (U.S. Patent # 7,264,800) from the United States Patent & Trademark Office, describing a method and composition for combining targeted DOS47 therapeutics with weakly basic chemotherapeutic drugs in adjunct treatment applications.

18 Sep 2007